<DOC>
	<DOCNO>NCT00079079</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , carboplatin , gemcitabine , work different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together either cisplatin carboplatin work treat patient locally advance , recurrent , metastatic malignant salivary gland tumor ( cancer ) .</brief_summary>
	<brief_title>Cisplatin Carboplatin Combined With Gemcitabine Treating Patients With Locally Advanced , Recurrent , Metastatic Malignant Salivary Gland Tumor</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine activity cisplatin carboplatin combination gemcitabine , term response rate , patient locally advance , recurrent , metastatic malignant salivary gland tumor . Secondary - Determine complete response patient treat regimen . - Determine duration response patient treat regimen . - Determine toxicity profile regimens patient . - Determine overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute day 1 8 . Patients also receive either cisplatin IV 1 hour day 2 OR carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients follow 4 week , every 3 month 1 year , every 6 month thereafter relapse . PROJECTED ACCRUAL : A total 11- 34 patient accrue study within 1.5-3 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant salivary gland tumor All histological subtypes eligible Locally advance , recurrent , metastatic disease Considered incurable radiotherapy surgery Low intermediategrade mucoepidermoid tumor acinic cell carcinoma allow provided patient symptomatic OR imminent risk develop symptom attributable metastatic disease Disease must meet 1 follow criterion : Metastatic disease chemonaïve Metastatic disease progress prior noncisplatin/carboplatin/gemcitabine regimen Local and/or distant recurrence curative surgery and/or radiotherapy Locally advance disease suitable surgery radiotherapy At least 1 site unidimensionally measurable disease document 1 following : At least 20 mm Xray , physical exam , nonspiral CT scan At least 10 mm spiral CT scan No bone metastases site measurable disease No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST/ALT great 3 time upper limit normal Renal Creatinine clearance least 60 mL/min ( cisplatin ) OR 3059 mL/min ( carboplatin ) Cardiovascular No symptomatic congestive heart failure No unstable angina No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious illness medical condition would preclude study participation No active uncontrolled infection No neurologic disorder psychiatric illness would preclude study compliance No malignancy within past 5 year except adequately treat nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy locally advance , recurrent , metastatic disease recover Must noncisplatin/carboplatin/gemcitabinecontaining regimen More 12 month since prior adjuvant chemotherapy ( include cisplatin/carboplatinbased regimen ) recover No prior gemcitabine Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy recover No prior radiotherapy site measurable disease unless documented disease progression therapy Surgery See Disease Characteristics At least 21 day since prior surgery recover Other More 30 day since prior anticancer therapy More 30 day since prior investigational agent No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage II salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland acinic cell tumor</keyword>
	<keyword>salivary gland adenoid cystic carcinoma</keyword>
	<keyword>salivary gland poorly differentiate carcinoma</keyword>
	<keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>salivary gland malignant mixed cell type tumor</keyword>
	<keyword>salivary gland adenocarcinoma</keyword>
	<keyword>salivary gland anaplastic carcinoma</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
</DOC>